Antithrombin Market :By Size, Supplier, Demand Analysis, Type, Statistics, Regions and Industry Key Manufacture

SDKI Inc. published a new report on the Antithrombin Market-Global Forecasts 2022-2031. This study includes the statistical and analytical approaches needed to grow the antithrombin market. The key industry insights provided in the report provide readers with better ideas about market overviews regarding existing market scenarios. In addition, the report contains a detailed discussion of current and future market trends related to market growth.

Report sample URL
https://www.sdki.jp/sample-request-111109

The antithrombin market is estimated to reach US $ 880 million by 2031 from a market value of US $ 580 million in 2022 and is expected to grow at a CAGR of 5.3% during the 2022-2031 forecast period.

Antithrombin is a protein present in blood that inhibits blood coagulation by inactivating thrombin. Antithrombin is produced in the liver and is composed of 432 amino acids. There are two main reasons for antithrombin deficiency: acquired antithrombin deficiency due to diseases such as nephrotic syndrome, liver failure, severe trauma, and metastatic tumors, and hereditary antithrombin deficiency due to genetic mutations or abnormalities.

Global demand for antithrombin over the next few years due to increased incidence of various health conditions such as sepsis, disseminated intravascular coagulation (DIC), congenital antithrombin deficiency, and extracorporeal membrane oxygenation (ECMO) Is expected to increase. Increasing demand and open heart surgery are also contributing to the growth of the antithrombin market. Products on the global antithrombin market are absolutely essential for the long-term treatment of thrombotic diseases. This has a positive impact on the sales and production of antithrombin drugs in the global antithrombin market.

However, the increased use of biopharmaceuticals and the high costs associated with antithrombin may curb the growth of the antithrombin market during the forecast period.

Meanwhile, the increased prevalence of hereditary antithrombin deficiency and the adoption of new therapies are projected to drive the growth of the global antithrombin market during the forecast period. Antithrombin is approved by the FDA as an anticoagulant and is indicated for venous thromboembolism in patients with hereditary antithrombin deficiency. Antithrombin is also used to treat disseminated intravascular coagulation (DIC) and extracorporeal membrane oxygenation (ECMO). Therefore, the increased prevalence of hereditary antithrombin deficiency increases the demand for products. This will drive the growth of the antithrombin market.

Report sample URL
https://www.sdki.jp/sample-request-111109

Antithrombin Market Segment

The antithrombin market is divided by application (treatment, research, and diagnosis), source (human, goat milk), dosage form (freeze-dried and liquid), and region. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.

Regional overview of the antithrombin market

antithrombin market is further subdivided based on the region, and the market growth of each country is evaluated. These include North America (US, Canada, and other North America), Europe (Germany, France, Italy, Spain, UK, and other Europe), Asia Pacific (China, Japan, India, Australia, Singapore, and others). Asia Pacific) and other regions.

The Asia-Pacific antithrombin market is expected to show high growth during the forecast period. This is due to developing countries such as India and China adopting new treatment procedures and techniques to combat a variety of diseases. In addition, the increased non-refundable income of developing countries and the increased ability to invest more money for advanced medical care will create more opportunities for the antithrombin market in the Asia-Pacific region.

Key players in the antithrombin market

Key players in the antithrombin market include rEVO Biologics, Inc., Grifols, Shire plc., CSL Limited, Kedrion SpA, Octapharma AG, Dem ilac Inc., Lee Bisolutions, Diapharma, Scripps Laboratories, Inc. and others. The survey includes a detailed competitive analysis of these major companies in the antithrombin market, corporate profiles, recent developments, and key market strategies.

Details of the research report
https://www.sdki.jp/press-details/antithrombin-market/697

Contact Us

Hina Miyazu
15/F Cerulean Tower, 26-1 Sakuragaoka-cho
Tokyo, Shibuya-ku, Japan
+ 81345720790
sales@sdki.jp

SDKI Inc. Company Profile

SDKI Inc.'s goal is market scenarios in various countries such as Japan, China, the United States, Canada, the United Kingdom, and Germany. Is to clarify. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With SDKI gaining trust and a customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.

This release was published on openPR.